Abstract
BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 212-214 |
| Number of pages | 3 |
| Journal | Journal of Urology |
| Volume | 147 |
| Issue number | 1 |
| State | Published - 1992 |
Fingerprint
Keywords
- BCG vaccine
- bladder neoplasms, immunotherapy, adoptive
ASJC Scopus subject areas
- Urology
Cite this
Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. / Riggs, D. R.; Tarry, W. F.; DeHaven, J. I.; Sosnowski, J.; Lamm, D. L.
In: Journal of Urology, Vol. 147, No. 1, 1992, p. 212-214.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy
AU - Riggs, D. R.
AU - Tarry, W. F.
AU - DeHaven, J. I.
AU - Sosnowski, J.
AU - Lamm, D. L.
PY - 1992
Y1 - 1992
N2 - BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.
AB - BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.
KW - BCG vaccine
KW - bladder neoplasms, immunotherapy, adoptive
UR - http://www.scopus.com/inward/record.url?scp=0026542821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026542821&partnerID=8YFLogxK
M3 - Article
C2 - 1729535
AN - SCOPUS:0026542821
VL - 147
SP - 212
EP - 214
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 1
ER -